Larotaxel

DB12984InvestigationalSmall molecule

Larotaxel has been used in trials studying the treatment of Cancer, Metastases, Breast Cancer, Breast Neoplasms, and Pancreatic Neoplasms, among others.

Mechanism: Pharmacologically active on Tubulin
Curator reviewed
Formula / weight: C₄₅H₅₃NO₁₄ · 831.912 g/mol (avg)
Code names: XRP-9881

Resolves to

Compound

UNIITWQ8K8A81YCAS156294-36-9PubChem6918260

Structure

InChIKeyDXOJIXGRFSHVKA-BZVZGCBYSA-NSMILES

CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@@]34OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Larotaxel, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account